Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05144529
Title A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC (TOP2101)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Scott Antonia

lung non-small cell carcinoma


Ipilimumab + Nivolumab

Evolocumab + Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.